Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Deffered Revenue (2022 - 2025)

Historic Non-Current Deffered Revenue for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $8.6 million.

  • Stoke Therapeutics' Non-Current Deffered Revenue rose 322.04% to $8.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 322.04%. This contributed to the annual value of $33.1 million for FY2023, which is 1026.16% down from last year.
  • Stoke Therapeutics' Non-Current Deffered Revenue amounted to $8.6 million in Q3 2025, which was up 322.04% from $9.6 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Non-Current Deffered Revenue high stood at $49.5 million for Q1 2022, and its period low was $8.3 million during Q3 2024.
  • Over the past 4 years, Stoke Therapeutics' median Non-Current Deffered Revenue value was $33.6 million (recorded in 2023), while the average stood at $28.8 million.
  • As far as peak fluctuations go, Stoke Therapeutics' Non-Current Deffered Revenue plummeted by 7964.4% in 2024, and later soared by 322.04% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $36.9 million in 2022, then fell by 10.26% to $33.1 million in 2023, then plummeted by 74.93% to $8.3 million in 2024, then rose by 3.22% to $8.6 million in 2025.
  • Its last three reported values are $8.6 million in Q3 2025, $9.6 million for Q2 2025, and $10.3 million during Q1 2025.